GSA Capital Partners LLP Has $61,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

GSA Capital Partners LLP lowered its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 87.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 17,142 shares of the company’s stock after selling 118,079 shares during the period. GSA Capital Partners LLP’s holdings in Fulcrum Therapeutics were worth $61,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in FULC. China Universal Asset Management Co. Ltd. increased its stake in Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after acquiring an additional 4,701 shares during the period. SG Americas Securities LLC lifted its position in Fulcrum Therapeutics by 26.5% in the third quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after purchasing an additional 6,926 shares during the period. Algert Global LLC boosted its stake in Fulcrum Therapeutics by 202.1% during the second quarter. Algert Global LLC now owns 41,303 shares of the company’s stock worth $256,000 after buying an additional 27,633 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Fulcrum Therapeutics in the 2nd quarter valued at $152,000. Finally, Caxton Associates LP acquired a new position in shares of Fulcrum Therapeutics in the 2nd quarter valued at $117,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $3.44 on Tuesday. The firm has a market capitalization of $185.55 million, a price-to-earnings ratio of -11.10 and a beta of 2.24. Fulcrum Therapeutics, Inc. has a 52 week low of $2.86 and a 52 week high of $13.70. The business’s fifty day moving average price is $3.41 and its two-hundred day moving average price is $6.28.

Analyst Ratings Changes

A number of brokerages have commented on FULC. Leerink Partnrs cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $22.00 to $3.00 in a research note on Thursday, September 12th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.